Christoph A. Schatz

BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models

Ningshu Liu, Bruce R. Rowley, Cathy Bull et al. · Molecular Cancer Therapeutics · 2013 · 251 citations

Molecular Pharmacology, Tumor Biology, Pi3k Inhibitors +15

Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody–Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect

Sven Golfier, Charlotte Kopitz, Antje Kahnert et al. · Molecular Cancer Therapeutics · 2014 · 245 citations

The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models

Antje M. Wengner, Gerhard Siemeister, Ulrich Lücking et al. · Molecular Cancer Therapeutics · 2019 · 200 citations

BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application

Gerhard Siemeister, Ulrich Lücking, Antje M. Wengner et al. · Molecular Cancer Therapeutics · 2012 · 154 citations · Full text

Oral Application, Chemoprevention Strategy, Retinoblastoma Protein +19

Exploratory Clinical Trial of (4 <i>S</i> )-4-(3-[18F]fluoropropyl)- <scp>l</scp> -glutamate for Imaging xC− Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer

Sora Baek, Chang‐Min Choi, Sei Hyun Ahn et al. · Clinical Cancer Research · 2012 · 130 citations · Full text